Dr. David Sherman, Seattle Biomedical Research Institute, “Seattle BioMed Tuberculosis Battle”
David Sherman is a full professor at the Seattle Biomedical Research Institute (Seattle BioMed). He earned his PhD in Biochemistry from Vanderbilt University, and performed post‑graduate work at the Rockefeller University and at Washington University in St. Louis. He began work on M. tuberculosis while at PathoGenesis Corp., where he played a lead role in the discovery and early development of the anti‑TB agent PA‑824 that is now in clinical trials. The Sherman laboratory studies virulence and latency of M. tuberculosis, and is also engaged in drug discovery efforts for this important pathogen. Current projects include detailed analyses of M. tuberculosis gene regulatory network in vitro and in vivo, and the pursuit of latency‑relevant drug targets. Lab members routinely employ a variety of research tools, including molecular genetics, systems biology, biochemistry, cultivation in vitro and in vivo, and whole genome microarray analysis.
On a personal level, Dr. Sherman routinely leaps tall buildings in a single bound and completes 60‑minute gourmet recipes in under 40 minutes. Children and dogs love him. He is far too modest to take pleasure from the fact that you are reading about him right now.